Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 28.
doi: 10.1097/HEP.0000000000001461. Online ahead of print.

E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p

Maider Apodaka-Biguri  1 , André L Simão  2 , Francisco González-Romero  1 , Daniela Mestre  1 , Pedro M Rodrigues  3   4   5 , Igor Aurrekoetxea  1   6 , Beatriz Gómez-Santos  1   6 , Xabier Buqué  1 , Ane Nieva-Zuluaga  1 , Mikel Ruiz de Gauna  1 , Idoia Fernandez-Puertas  1 , Paul Gomez-Jauregui  1 , Natalia Sainz-Ramirez  1 , Kendall Alfaro-Jiménez  1 , Ane Ortiz-Palma  1 , Estibaliz Castillero  1 , Ainhoa Iglesias-Ara  7 , Jone Mitxelena  5   7 , Ainhoa Eriz  7 , Ana M Aransay  3   8 , Juan-José Lozano  3   9 , Jose J G Marin  3   10 , Laura Izquierdo-Sanchez  2   3   4 , Maria J Perugorria  3   4 , Luis Bujanda  3   4 , Jesus M Banales  3   4   5   11 , César Martín  12   13 , Lorena Mosteiro  5 , Gaizka Errazti  5 , Wing-Kin Syn  1   14 , Luis Castaño  15   16 , Ana M Zubiaga  7 , Rui E Castro  2 , Patricia Aspichueta  1   3   6
Affiliations

E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p

Maider Apodaka-Biguri et al. Hepatology. .

Abstract

Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects a heterogeneous group of patients. Among them, those with a cholestatic profile show worse outcomes. Here, we investigated whether E2F2 is involved in MASLD-associated cholestasis and, if so, the role of miRNAs.

Approach and results: E2f2 -knockout ( E2f2-/- ) and wild-type (WT) mice were fed a choline-deficient high-fat diet (ChD-HFD) or an HFD after injection of diethylnitrosamine (DEN-HFD) to induce metabolic dysfunction-associated steatohepatitis (MASH). E2F2 was overexpressed in the liver by AAV8. Cholestasis was induced by bile duct ligation or by a 3,5-diethoxycarbonyl-1,4-dihydrocollidine-enriched diet. microRNA sequencing was performed. Two biopsy-proven MASLD patient cohorts were used. E2F2 deficiency resulted in increased synthesis and excretion of cholesterol, phosphatidylcholine, and bile acids, reducing their storage in the liver while increasing their presence in feces. This was consistent with increased expression of genes involved in biliary lipid metabolism, reduced inflammation and fibrosis, and the generation of a distinct miRNA profile, thereby preventing MASH. Liver-specific induction of E2F2 in vivo hampered the transcriptional program involved in biliary lipid metabolism and upregulated miR-34a-5p, which was downregulated in E2f2-/- mice. The protective effects observed in E2f2-/- mice were lost when a miR-34a-5p mimic was used. Hepatic miR-34a-5p levels were elevated in patients with advanced fibrosis, inflammation, steatosis score, cholelithiasis, and increased serum bile acids and biliary lipids. E2f2 deficiency conferred protection against cholestatic liver injury.

Conclusions: E2F2 deficiency protects against MASH and cholestasis, preventing cholesterol accumulation, fibrosis, and inflammation through modulation of miR-34a-5p. This could provide therapeutic benefits for patients with cholestatic MASH.

Keywords: E2F; MASH; MASLD; bile; bile acids; cholestasis; cholesterol; metabolism; miR-34a-5p; phospholipids.

PubMed Disclaimer

References

    1. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851–861.
    1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–1986.
    1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology. 2023;77:1335–1347.
    1. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: A consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60–78.
    1. Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, et al. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis. J Gastroenterol. 2024;59:586–597.

LinkOut - more resources